VistaGen Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.89 |
Market Cap |
$30.01 M |
Shares Outstanding |
42.62 M |
Public Float |
39.65 M |
Address |
343 Allerton Avenue South San Francisco California 94080 United States |
Employees | - |
Website | http://www.vistagen.com |
Updated | 07/08/2019 |
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H. |